[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628277":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":26,"locations":34,"responsibleParty":133,"collaborators":11,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":11,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":11,"enrollmentInfo":144,"targetDuration":11,"studyType":147,"phases":148,"briefSummary":150,"conditions":151,"keywords":155,"overallStatus":161,"whyStopped":11,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of Nivolumab + Relatlimab Fixed-Dose Combination (FDC)","EXPERIMENTAL",null,[13],"Drug: Nivolumab + Relatlimab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Nivolumab + Relatlimab","Specified dose on specified days",[9],[21,22],"Relopduo","BMS-986213",[24],{"name":5,"affiliation":5,"role":25},"STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":33,"role":29,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[35,51,63,76,88,100,112,124],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Local Institution - 0009","Navi Mumbai","Maharashtra","400614","India","IN",{"type":43,"coordinates":44},"Point",[45,46],73.01582,19.03681,{"lat":46,"lon":45},[49],{"name":50,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0009",{"facility":52,"status":11,"city":53,"state":38,"zip":54,"country":40,"countryCode":41,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Local Institution - 0008","Pune","411017",{"type":43,"coordinates":56},[57,58],73.85535,18.51957,{"lat":58,"lon":57},[61],{"name":62,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0008",{"facility":64,"status":11,"city":65,"state":66,"zip":67,"country":40,"countryCode":41,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Local Institution - 0003","Bhubaneswar","Odisha","751007",{"type":43,"coordinates":69},[70,71],85.83385,20.27241,{"lat":71,"lon":70},[74],{"name":75,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0003",{"facility":77,"status":11,"city":78,"state":11,"zip":79,"country":40,"countryCode":41,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Local Institution - 0002","Chennai","600006",{"type":43,"coordinates":81},[82,83],80.27847,13.08784,{"lat":83,"lon":82},[86],{"name":87,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0002",{"facility":89,"status":11,"city":90,"state":11,"zip":91,"country":40,"countryCode":41,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Local Institution - 0006","Mumbai","400 012",{"type":43,"coordinates":93},[94,95],72.88261,19.07283,{"lat":95,"lon":94},[98],{"name":99,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0006",{"facility":101,"status":11,"city":102,"state":11,"zip":103,"country":40,"countryCode":41,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Local Institution - 0005","Nagpur","440001",{"type":43,"coordinates":105},[106,107],79.08491,21.14631,{"lat":107,"lon":106},[110],{"name":111,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0005",{"facility":113,"status":11,"city":114,"state":11,"zip":115,"country":40,"countryCode":41,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Local Institution - 0004","New Delhi","110029",{"type":43,"coordinates":117},[118,119],77.2148,28.62137,{"lat":119,"lon":118},[122],{"name":123,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0004",{"facility":125,"status":11,"city":114,"state":11,"zip":126,"country":40,"countryCode":41,"cosmosGeoPoint":127,"geoPoint":129,"contacts":130},"Local Institution - 0001","110085",{"type":43,"coordinates":128},[118,119],{"lat":119,"lon":118},[131],{"name":132,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0001",{"type":134,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628277","phase-4-a-study-to-assess-the-safety-and-tolerability-of-nivolumab--relatlimab-fixed-dose-combination-fdc-in-untreated-unresectable-or-metastatic-melanoma-participants-in-india-100628277",false,"NCT07459543","A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India","A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Previously Untreated, Unresectable or Metastatic Melanoma in India.","Inclusion Criteria\n\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\u002FLansky Performance Score ≥ 80% for minors (ages 12-17) ONLY.\n* Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) staging system (8th edition).\n* Participants must be treatment-naïve (ie, no prior systemic anticancer therapy for unresectable or metastatic melanoma).\n* Participants must have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.\n* Participants must have completed prior radiotherapy at least 2 weeks prior to study treatment administration.\n* Individuals of Childbearing Potential (IOCBP) must not be pregnant or breastfeeding.\n\nExclusion Criteria\n\n* Participants must not have active brain metastases or leptomeningeal metastases.\n* Participants must not have uveal melanoma.\n* Participants must not have an active, known, or suspected autoimmune disease.\n* Participants must not have a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment.\n* Participants must not have a history of myocarditis.\n* Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways. Prior treatment with relatlimab or any other with LAG-3 targeted agents.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","12 Years",{"count":145,"type":146},30,"ESTIMATED","INTERVENTIONAL",[149],"PHASE4","The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in untreated, unresectable or metastatic melanoma participants in India",[152,153,154],"Untreated Melanoma","Unresectable Melanoma","Metastatic Melanoma",[156,157,158,40,159,160],"Skin Cancer","Malignant Melanoma","Immunotherapy","Nivolumab","Relatlimab","NOT_YET_RECRUITING","2026-03-05",{"date":164,"type":165},"2026-03-09","ACTUAL",{"date":167,"type":146},"2026-11-15",{"date":169,"type":146},"2029-05-28",{"name":5,"class":6},8]